QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=9A6DB3B64EC4691E87DB5822539F917C;jsessionid=021395EE77A032A88963306DAA958A91;jsessionid=CB11B5CE661A3D27EBAFD0356E2F4231;jsessionid=0593F67DC103419B12CCEEDD229B4D97;jsessionid=BE6C4AEEFCB5D4AE2066D8B5552CEA74;jsessionid=02FFF1BE4999AADDD12CEF2DEB8F2FFA;jsessionid=333A4B4D123176E0F136EC577CD93D99;jsessionid=81CE9132D4AA8C2DD1F5E1C92671BD63 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Identification of novel regulatory NFAT and TFII-I binding elements in the calbindin-D28k promoter i…

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=9A6DB3B64EC4691E87DB5822539F917C;jsessionid=021395EE77A032A88963306DAA958A91;jsessionid=CB11B5CE661A3D27EBAFD0356E2F4231;jsessionid=0593F67DC103419B12CCEEDD229B4D97;jsessionid=BE6C4AEEFCB5D4AE2066D8B5552CEA74;jsessionid=02FFF1BE4999AADDD12CEF2DEB8F2FFA;jsessionid=333A4B4D123176E0F136EC577CD93D99;jsessionid=81CE9132D4AA8C2DD1F5E1C92671BD63